JNJ
186.79
+0.34%↑
ABT
125.77
+1.66%↑
TMO
565.15
+0.26%↑
ISRG
538.71
-0.99%↓
DHR
213.79
-0.14%↓
JNJ
186.79
+0.34%↑
ABT
125.77
+1.66%↑
TMO
565.15
+0.26%↑
ISRG
538.71
-0.99%↓
DHR
213.79
-0.14%↓
JNJ
186.79
+0.34%↑
ABT
125.77
+1.66%↑
TMO
565.15
+0.26%↑
ISRG
538.71
-0.99%↓
DHR
213.79
-0.14%↓
JNJ
186.79
+0.34%↑
ABT
125.77
+1.66%↑
TMO
565.15
+0.26%↑
ISRG
538.71
-0.99%↓
DHR
213.79
-0.14%↓
JNJ
186.79
+0.34%↑
ABT
125.77
+1.66%↑
TMO
565.15
+0.26%↑
ISRG
538.71
-0.99%↓
DHR
213.79
-0.14%↓
24h
Current
Min
Max
Income | 78M 75M |
|---|---|
Sales | 5.5M 26M |
Profit margin | 288.656 |
Employees | 59 |
EBITDA | -73M -71M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +139.96% upside |
Next Earnings | 5 lis 2025 |
|---|
Market Cap | -18M 622M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24.5 USD 139.96%
High 29 USD
Low 18 USD
Based on 5 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$